Eupraxia Pharmaceuticals Inc.
EPRXF · OTC
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.23 | -0.05 | 0.23 | 0.25 |
| FCF Yield | -7.91% | -6.98% | -0.63% | -4.16% |
| EV / EBITDA | -12.11 | -10.31 | -30.76 | -20.23 |
| Quality | ||||
| ROIC | -36.39% | -24.13% | -52.19% | -29.16% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.28 | 1.01 | 0.20 | 0.69 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -27.72% | -798.35% | 88.44% | -39.61% |
| Safety | ||||
| Net Debt / EBITDA | 2.86 | 4.44 | 2.00 | 2.08 |
| Interest Coverage | -23.26 | -28.11 | 87.29 | -19.90 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 25,230.50 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |